A new treatment proposed for lung transplant rejection

El-Sayed, Ghassan
February 2008
Thorax;Feb2008, Vol. 63 Issue 2, p134
Academic Journal
The article discusses the recommendation of alemtuzumab as treatment for lung transplant rejection. Alemtuzumab is a monoclonal antibody to the CD52 antigen which is expressed on T cells, B cells, monocytes, macrophages and platelets and stimulate lymphocyte reduction. It is also possibly helpful in treating refractory acute rejection or bronchiolitis obliterans syndrome in lung transplant for those receivers who failed prior conventional therapy.


Related Articles

  • Post-Transplant Lymphoproliferative Disease: Association with Induction Therapy? Dharnidharka, Vikas R. // Drugs;2006, Vol. 66 Issue 4, p429 

    In the last 2 decades, several polyclonal and monoclonal antibodies have been developed for induction therapy in the early post solid-organ transplantation period. The use of these antibodies has been associated, for the most part, with a decrease in early acute rejection rates. However, there...

  • Split Rejection in Vascularized Composite Allotransplantation. Sinha, Indranil; Pomahac, Bohdan // ePlasty: Open Access Journal of Plastic Surgery;2013, Vol. 13, p461 

    Introduction: Graft monitoring following vascularized composite allotransplantation (VCA) relies primarily on serial skin biopsy. However, given that VCA comprised multiple tissue types, skin biopsy may not accurately reflect rejection in other transplanted tissue. Methods: A review of the...

  • Trasplante renal de donador vivo relacionado en una paciente altamente sensibilizada vs CMH Clase I y Clase II. Presentación de un caso resuelto con éxito. Zaltzman-Girshevich, Samuel; Espinosa, Francisco; Béjar, Yolanda; De Leo, Claudia; Manzano-Jiménez, Avelina; Calderón-Mendieta, Francisco // Acta Pediatrica de Mexico;mar/abr2008, Vol. 29 Issue 2, p61 

    The presence of preformed antibodies has been the cause of many failures in organ transplantation; because of this we describe a successful transplantation in a 17 year-old female adolescent, who rejected the kidney from her mother the first two weeks after surgery: she developed antibodies...

  • The Search for Immunosuppressive Therapies to Induce Tolerance in Organ Transplantation. Kuei-Chen Chiang; Ohmori, Naoya; Goto, Takeshi // Endocrine, Metabolic & Immune Disorders - Drug Targets;Jun2011, Vol. 11 Issue 2, p173 

    No abstract available.

  • Efficacy of Alemtuzumab in Organ Transplantation: Current Clinical Status. Ciancio, Gaetano; Burke, George W.; Warque, Maria E.; Miller, Joshua // BioDrugs;2006, Vol. 20 Issue 2, p85 

    An overview of the past 5 years of clinical renal transplantation would include progress in (i) the development of protocols with new induction agents (non-depleting versus depleting monoclonal and polyclonal antibodies) designed to reduce the incidence and severity of acute rejection, (ii) the...

  • Distribution of the αGal- and the non-αGal T-antigens in the pig kidney: potential targets for rejection in pig-to-man xenotransplantation. Kirkeby, Svend; Mikkelsen, Hanne B. // Immunology & Cell Biology;Jun2008, Vol. 86 Issue 4, p363 

    Carbohydrate antigens, present on pig vascular endothelial cells, seem to be the prime agents responsible for graft rejection, and although genetically modified animals that express less amounts of carbohydrate antigen are available, it is still useful to decide the localization of the reactive...

  • Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Adu, Dwomoa; Cockwell, Paul; Ives, Natalie J; Shaw, Jonathan; Wheatley, Keith // BMJ: British Medical Journal (International Edition);4/12/2003, Vol. 326 Issue 7393, p789 

    Objective: To study the effect of interleukin-2 receptor monoclonal antibodies on acute rejection episodes, graft loss, deaths, and rate of infection and malignancy in patients with renal transplants. Design: Meta-analysis of published data. Data sources: Medline, Embase, and Cochrane library...

  • New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation. Anlun Ma; Liangyan Zhang; Xiliang Wang; Huifang Chen // Current Drug Safety;May2009, Vol. 4 Issue 2, p155 

    The activation of T cells depends upon two signals, antigen-specific signal through the T cell receptor and nonantigen-specific costimulatory signal through antigen present cell surface molecules. In clinical transplantation, activated T cells orchestrate the immune response and result in...

  • A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients. Iacono, Aldo T.; Johnson, Bruce A.; Grgurich, Wayne F.; Youssef, J. Georges; Corcoran, Timothy E.; Seiler, Deidre A.; Dauber, James H.; Smaldone, Gerald C.; Zeevi, Adriana; Yousem, Samuel A.; Fung, John J.; Burckart, Gilbert J.; McCurry, Kenneth R.; Griffith, Bartley P. // New England Journal of Medicine;1/12/2006, Vol. 354 Issue 2, p141 

    Background: Conventional regimens of immunosuppressive drugs often do not prevent chronic rejection after lung transplantation. Topical delivery of cyclosporine in addition to conventional systemic immunosuppression might help prevent acute and chronic rejection events. Methods: We conducted a...


Read the Article


Sign out of this library

Other Topics